Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivekimig in Adults With Moderate to Severe Crohn's Disease
NCT06958536Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of brivekimig in Crohn's disease (3 arms), sponsored by Sanofi. Primary endpoint: Percentage of participants who achieve endoscopic response at 16 weeks. Started Jun 2025; status: recruiting.
02
Drugs
brivekimig
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06958536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06958536.